Benedetta Mussolin

Benedetta Mussolin

Auto-generated profile, based on publicly available information

Benedetta Mussolin

Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Giulia SiravegnaGiulia Siravegna
Giulia Siravegna
BMBenedetta Mussolin
Benedetta Mussolin
MBMichela Buscarino
Michela Buscarino
GCGiorgio Corti
Giorgio Corti
ACAndrea Cassingena
Andrea Cassingena
ABAlberto Bardelli
Alberto Bardelli

29 November 2017 in Nature
Verified
Journal Article
Closed access
PDF file
Giovanni GermanoGiovanni Germano
Giovanni Germano
SLSimona Lamba
Simona Lamba
GRGiuseppe Rospo
Giuseppe Rospo
LBLudovic Barault
Ludovic Barault
AMAlessandro Magrì
Alessandro Magrì
ABAlberto Bardelli
Alberto Bardelli

1 March 2017 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
LGLipika Goyal
Lipika Goyal
SSSupriya K. Saha
Supriya K. Saha
LLLeah Y. Liu
Leah Y. Liu
Giulia SiravegnaGiulia Siravegna
Giulia Siravegna
ILIgnaty Leshchiner
Ignaty Leshchiner
AZAndrew X. Zhu
Andrew X. Zhu
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The FGFR inhibitor BGJ398 displayed encouraging efficacy in patients with FGFR2 fusion–positive ICC in a phase II trial, but the durability of response was limited in some patients. Here, we report the molecular basis for acquired resistance to BGJ398 in three patients via integrative genomic characterization of cell-free circulating tumor DNA (cfDNA), primary tumors, and metastases. Serial analysis of cfDNA demonstrated multiple recurrent point mutations in the FGFR2 kinase domain at progression. Accordingly, biopsy of post-progression lesions and rapid autopsy revealed marked inter- and intralesional heterogeneity, with different FGFR2 mutations in individual resistant clones. Molecular modeling and in vitro studies indicated that each mutation led to BGJ398 resistance and was surmountable by structurally distinct FGFR inhibitors. Thus, polyclonal secondary FGFR2 mutations represent an important clinical resistance mechanism that may guide the development of future therapeutic strategies. Significance: We report the first genetic mechanisms of clinical acquired resistance to FGFR inhibition in patients with FGFR2 fusion–positive ICC. Our findings can inform future strategies for detecting resistance mechanisms and inducing more durable remissions in ICC and in the wide variety of cancers where the FGFR pathway is being explored as a therapeutic target. Cancer Discov; 7(3); 252–63. ©2016 AACR. See related commentary by Smyth et al., p. 248. This article is highlighted in the In This Issue feature, p. 235

19 May 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
VAVito Amodio
Vito Amodio
RYRona Yaeger
Rona Yaeger
PAPamela Arcella
Pamela Arcella
CCCarlotta Cancelliere
Carlotta Cancelliere
SLSimona Lamba
Simona Lamba
SMSandra Misale
Sandra Misale
Most patients with KRASG12C–mutant non–small cell lung cancer (NSCLC) experience clinical benefit from selective KRASG12C inhibition, whereas patients with colorectal cancer bearing the same mutation rarely respond. To investigate the cause of the limited efficacy of KRASG12C inhibitors in colorectal cancer, we examined the effects of AMG510 in KRASG12C colorectal cancer cell lines. Unlike NSCLC cell lines, KRASG12C colorectal cancer models have high basal receptor tyrosine kinase (RTK) activation and are responsive to growth factor stimulation. In colorectal cancer lines, KRASG12C inhibition induces higher phospho-ERK rebound than in NSCLC cells. Although upstream activation of several RTKs interferes with KRASG12C blockade, we identify EGFR signaling as the dominant mechanism of colorectal cancer resistance to KRASG12C inhibitors. The combinatorial targeting of EGFR and KRASG12C is highly effective in colorectal cancer cells and patient-derived organoids and xenografts, suggesting a novel therapeutic strategy to treat patients with KRASG12C colorectal cancer. Significance: The efficacy of KRASG12C inhibitors in NSCLC and colorectal cancer is lineage-specific. RTK dependency and signaling rebound kinetics are responsible for sensitivity or resistance to KRASG12C inhibition in colorectal cancer. EGFR and KRASG12C should be concomitantly inhibited to overcome resistance to KRASG12C blockade in colorectal tumors. See related commentary by Koleilat and Kwong, p. 1094. This article is highlighted in the In This Issue feature, p. 1079

1 February 2016 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
Mariangela RussoMariangela Russo
Mariangela Russo
Giulia SiravegnaGiulia Siravegna
Giulia Siravegna
LBLawrence S. Blaszkowsky
Lawrence S. Blaszkowsky
GCGiorgio Corti
Giorgio Corti
Giovanni CrisafulliGiovanni Crisafulli
Giovanni Crisafulli
RCRyan B. Corcoran
Ryan B. Corcoran
How genomic heterogeneity associated with acquired resistance to targeted agents affects response to subsequent therapy is unknown. We studied EGFR blockade in colorectal cancer to assess whether tissue and liquid biopsies can be integrated with radiologic imaging to monitor the impact of individual oncogenic alterations on lesion-specific responses. Biopsy of a patient's progressing liver metastasis following prolonged response to cetuximab revealed a MEK1K57T mutation as a novel mechanism of acquired resistance. This lesion regressed upon treatment with panitumumab and the MEK inhibitor trametinib. In circulating tumor DNA (ctDNA), mutant MEK1 levels declined with treatment, but a previously unrecognized KRASQ61H mutation was also identified that increased despite therapy. This same KRAS mutation was later found in a separate nonresponding metastasis. In summary, parallel analyses of tumor biopsies and serial ctDNA monitoring show that lesion-specific radiographic responses to subsequent targeted therapies can be driven by distinct resistance mechanisms arising within separate tumor lesions in the same patient. Significance: Molecular heterogeneity ensuing from acquired resistance drives lesion-specific responses to subsequent targeted therapies. Analysis of a single-lesion biopsy is inadequate to guide selection of subsequent targeted therapies. ctDNA profiles allow the detection of concomitant resistance mechanisms residing in separate metastases and assessment of the effect of therapies designed to overcome resistance. Cancer Discov; 6(2); 147–53. ©2015 AACR. See related commentary by Hiley and Swanton, p. 122. This article is highlighted in the In This Issue feature, p. 109

1 October 2019 in Annals of Oncology
Verified
Journal Article
Open access
GSG. Siravegna
G. Siravegna
BMB. Mussolin
B. Mussolin
TVTiziana Venesio
Tiziana Venesio
SMS. Marsoni
S. Marsoni
JSJoan Seoane
Joan Seoane
ABAlberto Bardelli
Alberto Bardelli
Cell-free DNA fragments are shed into the bloodstream by tumor cells. The analysis of circulating tumor DNA (ctDNA), commonly known as liquid biopsy, can be exploited for a variety of clinical applications. ctDNA is being used to genotype solid cancers non-invasively, to track tumor dynamics and to detect the emergence of drug resistance. In a few settings, liquid biopsies have already entered clinical practice. For example, ctDNA is used to guide treatment in a subset of lung cancers. In this review, we discuss how recent improvements in the sensitivity and accuracy of ctDNA analyses have led to unprecedented advances in this research field. We further consider what is required for the routine deployment of liquid biopsies in the clinical diagnostic space. We pinpoint technical hurdles that liquid biopsies have yet to overcome, including preanalytical and analytical challenges. We foresee how liquid biopsies will transform clinical practice: by complementing (or replacing) imaging to monitor treatment response and by detecting minimal residual disease after surgery with curative intent.